Harvard Bioscience (HBIO) Equity Ratio (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Equity Ratio data on file, last reported at 0.13 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.13, down 30.66% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.13 (down 30.66% YoY), and the FY2025 annual result was 0.17, down 65.71% from the prior year.
• Equity Ratio retreated to 0.13 in Q1 2026 per HBIO's latest filing, from 0.17 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.53 in Q4 2023 and troughed at 0.13 in Q1 2026.
• A 5-year average of 0.41 and a median of 0.5 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio gained 8.58% in 2023, then tumbled 65.71% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.5 in 2022, then climbed by 7.07% to 0.53 in 2023, then retreated by 5.98% to 0.5 in 2024, then plunged by 65.71% to 0.17 in 2025, then retreated by 24.85% to 0.13 in 2026.
• Business Quant data shows HBIO's Equity Ratio at 0.13 in Q1 2026, 0.17 in Q4 2025, and 0.18 in Q3 2025.